Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Feb 16, 2024 9:21pm
128 Views
Post# 35885415

RE:RE:RE:AEZS approached CZO

RE:RE:RE:AEZS approached CZOAEZS put the squeeze on CZO after Q2 results were released and the new company then became a 50/50 split. No doubt that any positive news for CEAPRO such as the commercial licensing of CoQ10 in H2 or AV phase 1/2a results (if started on time) would have led to re-negotiating this ratio, or the potential termination of the agreement. Gilles really wanted this deal which would stroke his ego to be a CEO of a NASDAQ listed biopharma company.

OATS you and your group can put an end to this sham of a merger and let shareholders take back the company. Gilles has proven he has no credibility. Don't be persuaded by his hollow words.


<< Previous
Bullboard Posts
Next >>